+ Watch XLRN
on My Watchlist
I'm continuing to suppress my skepticism on new IPO's, hoping not to be stuck on the sideline next time there's an Intercept. Acceleron is yet another leap of faith, as I haven't yet had time to ground myself in the science behind the company's pipeline of TGF beta-related drugs. For now, the market has spotted Acceleron a billion plus valuation presumably on the potential of sotatercept to compete with the erythropoietin analogues for the renal failure anemia market. There was another competitor not too long ago called Omontys - didn't really work out too well. Hopefully sotatercept fares better.
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions